Joy · La Clinica terapeutica 2026 · narrative review · n=?

The therapeutic potential of N-acetylcysteine across multiple organ systems: a narrative review.

Level 5 - mechanism / opinion, no new human data

Narrative review synthesizing preclinical and clinical literature without systematic review methodology

PubMed 42340796 · doi:10.7417/CT.2026.2089 · record verified 2026-08-26

What was done

This narrative review synthesized preclinical (in vitro and in vivo) and clinical evidence on the multi-organ therapeutic potential and mechanisms of N-acetylcysteine (NAC). The authors examined biological actions—including glutathione synthesis, direct free-radical scavenging, and modulation of Nrf2 and NF-κB—across respiratory, cardiovascular, renal, and central nervous system indications.

What was found

The abstract reports no numerical values, effect sizes, or statistical metrics. Qualitatively, NAC was reported to improve mucus clearance and reduce exacerbations in chronic obstructive pulmonary disease, show variable benefits in idiopathic pulmonary fibrosis, confer endothelial protection and enhance nitric oxide bioavailability with mixed mortality and arrhythmia outcomes in cardiovascular trials, reduce markers of contrast-induced and perioperative acute kidney injury, and exhibit preclinical neuroprotective effects with inconsistent clinical results. Reported adverse events were primarily mild gastrointestinal symptoms.

Why it matters

It maps the broad biological rationale and clinical scope for NAC beyond its classic roles as a mucolytic and acetaminophen antidote, highlighting where clinical trial evidence diverges from preclinical promise.

Limits

As a narrative review, it lacks systematic search protocols, formal study quality assessment, and meta-analytic pooling. The abstract provides no quantitative data. Primary evidence across several surveyed indications remains limited by inconsistent trial findings, variable dosing strategies, and bioavailability constraints.

Cited by